BG107856A - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms - Google Patents

Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Info

Publication number
BG107856A
BG107856A BG107856A BG10785603A BG107856A BG 107856 A BG107856 A BG 107856A BG 107856 A BG107856 A BG 107856A BG 10785603 A BG10785603 A BG 10785603A BG 107856 A BG107856 A BG 107856A
Authority
BG
Bulgaria
Prior art keywords
processes
forms
novel
preparation
preparing
Prior art date
Application number
BG107856A
Other languages
Bulgarian (bg)
English (en)
Inventor
Judith Aronhime
Rami Lidor-Hadas
Valerie Niddam-Hildesheim
Revital Lifshitz-Liron
Eti Kovalesvski-Ishai
Guy Samburski
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27540285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG107856(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of BG107856A publication Critical patent/BG107856A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG107856A 2000-11-30 2003-05-29 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms BG107856A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25007200P 2000-11-30 2000-11-30
US26789701P 2001-02-09 2001-02-09
US28187201P 2001-04-05 2001-04-05
US31214401P 2001-08-13 2001-08-13
US32652901P 2001-10-01 2001-10-01

Publications (1)

Publication Number Publication Date
BG107856A true BG107856A (en) 2004-11-30

Family

ID=27540285

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107856A BG107856A (en) 2000-11-30 2003-05-29 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Country Status (23)

Country Link
US (15) US20020183378A1 (es)
EP (5) EP1363621A4 (es)
JP (2) JP2004514694A (es)
KR (1) KR100765871B1 (es)
CN (1) CN1489463A (es)
AU (1) AU2002217927A1 (es)
BG (1) BG107856A (es)
BR (1) BR0115892A (es)
CA (3) CA2689915A1 (es)
CZ (1) CZ20031766A3 (es)
DE (1) DE01998348T1 (es)
ES (2) ES2215495T1 (es)
HR (2) HRP20030523A2 (es)
HU (1) HUP0600538A3 (es)
IL (2) IL156055A0 (es)
IS (1) IS6829A (es)
MX (1) MXPA03004844A (es)
NO (1) NO20032425L (es)
PL (1) PL363228A1 (es)
SK (1) SK8062003A3 (es)
TR (1) TR200400815T3 (es)
WO (1) WO2002043732A1 (es)
YU (1) YU42803A (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36268E (en) * 1988-03-15 1999-08-17 Boehringer Mannheim Corporation Method and apparatus for amperometric diagnostic analysis
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL155734A0 (en) * 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
AU3289102A (en) * 2000-11-16 2002-06-11 Teva Pharma Hydrolysis of (R(R*,R*))-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CZ20032019A3 (cs) 2000-12-27 2003-10-15 Ciba Specialty Chemicals Holding Inc. Krystalické formy Atorvastatinu
EA005317B1 (ru) * 2001-06-29 2004-12-30 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1h-пиррол-1-гептановой кислоты кальциевой соли (2:1) (аторвастатин)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EP1414796A1 (en) * 2001-07-30 2004-05-06 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
TR200302281T2 (tr) * 2001-08-16 2004-09-21 Teva Pharmaceutical Industries Ltd. Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
PL372303A1 (en) * 2002-02-15 2005-07-11 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
MXPA04007995A (es) 2002-02-19 2004-11-26 Teva Pharma Desolvatacion de solvatos de hemicalcio de atorvastatina.
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
AU2003297594A1 (en) * 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
JP4901474B2 (ja) * 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド 置換ピロール誘導体
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
EP1577297A1 (en) 2004-03-17 2005-09-21 Ranbaxy Laboratories, Ltd. Process for the production of atorvastatin calcium in amorphous form
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
BRPI0511508A (pt) * 2004-05-24 2008-01-08 Warner Lambert Co formas de sais de atorvastatina, composição farmacêutica e processo
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE05774589T1 (de) * 2004-07-22 2007-08-09 Teva Pharmaceutical Industries Ltd. Neue kristallformen von atorvastatin-hemi-calcium und verfahren zu deren herstellung
CN101124230A (zh) * 2004-09-28 2008-02-13 特瓦制药工业有限公司 制备基本无杂质的阿托伐他汀钙形式的方法
JP2008514722A (ja) * 2004-09-30 2008-05-08 ドクター レディズ ラボラトリーズ リミテッド 非結晶性アトルバスタチンカルシウム
TW200942516A (en) * 2004-10-18 2009-10-16 Teva Pharma Processes for preparing amorphous atorvastatin hemi-calcium
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
EP1814541A4 (en) * 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd STABLE ATORVASTATIN FORMULATIONS
SI1698630T1 (sl) * 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
RO200700700A8 (ro) * 2005-04-08 2015-07-30 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
KR101329112B1 (ko) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
EP1808162A1 (en) 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
EP1923057A1 (en) 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
DE602006014193D1 (de) 2005-11-21 2010-06-17 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium
BRPI0610344A2 (pt) 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
JP2007246514A (ja) * 2006-02-14 2007-09-27 Toyama Chem Co Ltd ピペラシリンナトリウムの新規な結晶
AU2007219107B2 (en) * 2006-02-22 2012-12-06 Mylan Laboratories Ltd. New crystalline form of Atorvastatin hemi-calcium
EP1877375A1 (en) * 2006-03-01 2008-01-16 Teva Pharmaceutical Industries Ltd Process for preparing a crystalline form of atorvastatin hemi-calcium
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
EP2049102A4 (en) * 2006-07-14 2010-12-22 Ranbaxy Lab Ltd POLYMORPHIC FORMS OF AN HMG COA REDUCTASE HEATHER AND USE
US20100029743A1 (en) * 2006-09-27 2010-02-04 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
EP2128162A4 (en) * 2007-01-31 2011-05-25 Toyama Chemical Co Ltd NEW CRYSTAL OF PIPERACILIN SODIUM
WO2008108572A1 (en) * 2007-03-02 2008-09-12 Dong-A Pharm. Co., Ltd. Novel crystal forms of pyrrolylheptanoic acid derivatives
WO2008129562A2 (en) * 2007-04-20 2008-10-30 Morepen Laboratories Limited An improved process for the preparation of stable amorphous atorvastatin hemi calcium and their salts thereof
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009082362A1 (en) * 2007-11-05 2009-07-02 Ulkar Kimya San. Ve Tic. A.S. A method for producing statins in pure form
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101538237B (zh) * 2008-05-30 2011-04-06 天津和美生物技术有限公司 阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用
JP2011528231A (ja) 2008-07-17 2011-11-17 デラヴァル ホールディング エービー 食品および飲料の製造および取扱い設備の洗浄方法
EP2473515A4 (en) 2009-09-04 2013-11-27 Univ Toledo METHODS OF MAKING OPTICALLY PURE BETA-LACTONES FROM ALDEHYDES AND COMPOSITIONS OBTAINED THEREFROM
US11473032B2 (en) 2010-02-02 2022-10-18 Fuchs Petrolub Se Constant velocity joint having a boot
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN102766136A (zh) * 2012-08-07 2012-11-07 浙江宏元药业有限公司 一种制备阿托伐他汀钙中间体的方法
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN103641764B (zh) * 2013-11-25 2015-12-02 北京三泉医药技术有限公司 调节血脂的药物组合物
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN104983690A (zh) * 2015-08-18 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗冠心病的药物阿托伐他汀钙组合物干混悬剂
EP3272336A1 (de) * 2016-07-19 2018-01-24 Stada Arzneimittel Ag Atorvastatin-zusammensetzung

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115709A (en) * 1871-06-06 Improvement in curriers slickers
US99224A (en) * 1870-01-25 Improvement in pocket-sates for friction-matches
US2598627A (en) * 1949-10-11 1952-05-27 Robert Gair Co Inc Folding carton
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE4411536A1 (de) * 1994-04-02 1995-10-05 Cassella Ag Wasserquellbare hydrophile Polymere
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
IL128862A (en) 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6065729A (en) * 1998-01-28 2000-05-23 Prince Corporation Slide-out container holder
US5959156A (en) 1998-11-12 1999-09-28 Bp Amoco Corporation Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether
IN191236B (es) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
PT1235799E (pt) * 1999-11-17 2005-05-31 Teva Pharma Forma polimorfica de atorvastatina-calcio
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
WO2001044181A1 (en) 1999-12-17 2001-06-21 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
DE60024133T2 (de) 1999-12-17 2006-08-03 Pfizer Science And Technology Ireland Ltd., Dun Laoghaire Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
IL155734A0 (en) * 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
AU3289102A (en) * 2000-11-16 2002-06-11 Teva Pharma Hydrolysis of (R(R*,R*))-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CZ20032019A3 (cs) * 2000-12-27 2003-10-15 Ciba Specialty Chemicals Holding Inc. Krystalické formy Atorvastatinu
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (es) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
EA005317B1 (ru) * 2001-06-29 2004-12-30 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1h-пиррол-1-гептановой кислоты кальциевой соли (2:1) (аторвастатин)
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EP1414796A1 (en) 2001-07-30 2004-05-06 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
TR200302281T2 (tr) * 2001-08-16 2004-09-21 Teva Pharmaceutical Industries Ltd. Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler
US7563911B2 (en) 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
CA2467691A1 (en) 2001-11-30 2004-01-29 University Of Maryland, Baltimore Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
PL372303A1 (en) 2002-02-15 2005-07-11 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
MXPA04007995A (es) 2002-02-19 2004-11-26 Teva Pharma Desolvatacion de solvatos de hemicalcio de atorvastatina.
WO2003083638A2 (en) 2002-03-28 2003-10-09 Emc Corporation Data storage system
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CA2491051A1 (en) 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
EP1424324A1 (en) 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
AU2003297594A1 (en) 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US20040242670A1 (en) * 2003-06-02 2004-12-02 Sonny Sebastian Process for preparation of amorphous atorvastatin calcium
DE05774589T1 (de) * 2004-07-22 2007-08-09 Teva Pharmaceutical Industries Ltd. Neue kristallformen von atorvastatin-hemi-calcium und verfahren zu deren herstellung
TW200942516A (en) * 2004-10-18 2009-10-16 Teva Pharma Processes for preparing amorphous atorvastatin hemi-calcium
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i

Also Published As

Publication number Publication date
US7151183B2 (en) 2006-12-19
CN1489463A (zh) 2004-04-14
US20060058533A1 (en) 2006-03-16
IS6829A (is) 2003-05-27
JP2009120624A (ja) 2009-06-04
US6992194B2 (en) 2006-01-31
US7189861B2 (en) 2007-03-13
YU42803A (sh) 2006-05-25
SK8062003A3 (en) 2004-07-07
IL156055A0 (en) 2003-12-23
HUP0600538A3 (en) 2010-09-28
US20050261360A1 (en) 2005-11-24
US7256212B2 (en) 2007-08-14
US20050090542A1 (en) 2005-04-28
US7468444B2 (en) 2008-12-23
US20050267198A1 (en) 2005-12-01
US7456297B2 (en) 2008-11-25
PL363228A1 (en) 2004-11-15
BR0115892A (pt) 2003-10-28
US7342120B2 (en) 2008-03-11
KR100765871B1 (ko) 2007-10-11
MXPA03004844A (es) 2005-04-19
NO20032425L (no) 2003-07-25
CA2429590A1 (en) 2002-06-06
HUP0600538A2 (en) 2006-09-28
ES2437157T3 (es) 2014-01-09
EP1363621A1 (en) 2003-11-26
US20060106231A1 (en) 2006-05-18
US20060106232A1 (en) 2006-05-18
TR200400815T3 (tr) 2004-07-21
JP2004514694A (ja) 2004-05-20
ES2215495T1 (es) 2004-10-16
AU2002217927A1 (en) 2002-06-11
US7161012B2 (en) 2007-01-09
US20050282885A1 (en) 2005-12-22
CA2429590C (en) 2008-06-10
EP2192113A1 (en) 2010-06-02
IL156055A (en) 2010-12-30
KR20030059297A (ko) 2003-07-07
EP2194041A1 (en) 2010-06-09
EP1783113A2 (en) 2007-05-09
EP1363621A4 (en) 2005-12-28
CZ20031766A3 (cs) 2004-08-18
WO2002043732A1 (en) 2002-06-06
US20080214650A1 (en) 2008-09-04
US20020183378A1 (en) 2002-12-05
HRP20030523A2 (en) 2005-06-30
HRP20130545A2 (hr) 2013-11-08
CA2625277A1 (en) 2002-06-06
US7488750B2 (en) 2009-02-10
DE01998348T1 (de) 2004-08-26
US20060100267A1 (en) 2006-05-11
US7144916B2 (en) 2006-12-05
NO20032425D0 (no) 2003-05-28
US20060100446A1 (en) 2006-05-11
EP2192112B1 (en) 2013-08-28
US20050261361A1 (en) 2005-11-24
US20050004206A1 (en) 2005-01-06
CA2689915A1 (en) 2002-06-06
US20060100445A1 (en) 2006-05-11
EP2192112A1 (en) 2010-06-02
US20050261359A1 (en) 2005-11-24
EP1783113A3 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
BG107856A (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
MXPA03011329A (es) Antiinfecciosos novedosos.
BG101110A (en) Substituted pyrimidine compounds and their application
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
WO2004043918A3 (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
IN2012DE00109A (es)
MXPA04000889A (es) Formas cristalinas vi y vii de atorvastatina calcica.
EP1480950A4 (en) NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX
MY133969A (en) Indoloquinazolinones
AU2002353775A1 (en) Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
AU7027100A (en) Novel compounds
BG106002A (en) Process for preparing pesticidal intermediates
MXPA03010498A (es) Proceso para la preparacion de imipenem.
MXPA04005151A (es) Compuestos terapeuticos.
GB0108903D0 (en) Novel crystalline forms of a factor Xa inhibitor
LT2004018A (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
GB9806409D0 (en) Processes for preparing intermediates
IL148161A0 (en) Process for the preparation of 2-cyanopyridines
ZA983231B (en) Substituted benzyloxyimino compounds.
MXPA04000623A (es) Derivados de tetrahidropiridazina y su uso como pesticidas.
DE60212130D1 (en) Carvedilolpolymorph
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
MXPA05007696A (es) Modificacion cristalina de un complejo de manganeso.